Biotechnology major Biocon and German drug firm Evotec SE on Thursday said their subsidiaries have entered into a licensing agreement for a biosimilar asset.
The agreement has been signed between Biocon Biologics and Just - Evotec Biologics.
Through this in-licensing deal, Biocon Biologics has expanded its current therapeutic basket of biosimilars going beyond diabetes, oncology and immunology, the companies said a joint statement
Biocon Biologics will take this early-stage, pre-clinical biosimilar asset through end-to-end development, Investigational New Drug filing, manufacturing and commercialisation post-regulatory approval under its own label in global markets, it added.
Just Evotec Biologics has received a licence fee from Biocon Biologics and will be eligible to receive development, regulatory and commercial milestone payments, the statement said.
The companies however did not disclose any financial details of the licensing transaction.
"We are extremely confident of the ...
